Completed PHASE2 INTERVENTIONAL 2-arm NCT00655928

Modulation of Lung Injury Complicating Lung Resection

Sponsor: Imperial College London

Interventions 0.9% saline N-acetylcysteine

Updated 9 times since 2017 Last updated: Feb 3, 2020 Started: Aug 31, 2007 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00655928, this PHASE2 trial focuses on Acute Lung Injury and remains completed. Sponsored by Imperial College London, it has been updated 9 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Nov 2019 — Mar 2020 [monthly]

Completed PHASE2
Oct 2019 — Nov 2019 [monthly]

Completed PHASE2
Jun 2018 — Oct 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Imperial College London
Royal Brompton & Harefield NHS Foundation Trust
Royal College of Physicians

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom